3BP-227 / IPN01087 is targeting the neurotensin receptor 1 (NTR1) which is highly expressed on the cancer cells of ductal pancreatic adenocarcinoma and several other tumor entities. Using a theranostic approach, the compound is currently being developed for imaging and treatment of pancreatic adenocarcinoma and colorectal cancer. The program is partnered with IPSEN Pharma SAS who is sponsoring the ongoing phase I/II trial (NCT03525392).
FAP-2286 targets the fibroblast activation protein (FAP), a molecule that is expressed in large amounts on the surface of cancer-associated fibroblasts (CAFs), which play a major role in the growth and progression of epithelial cancers. Since more than 90% of all epithelial tumors contain FAP-expressing CAFs, FAP is a genuine pan-tumor target and allows the treatment of a variety of cancer indications such as breast, colorectal, pancreatic and lung cancer as well as rarer indications such as sarcomas. Clovis Oncology has obtained U.S. and global rights to the FAP-2286 program, excluding Europe (inclusive of Russia, Turkey and Israel), where 3BP retains rights. Clovis is currently planning to file an IND for FAP-targeted radiopharmaceutical therapy in H2 2020.
3B-401 is our development candidate binding to the GIP receptor (Glucose-dependent Insulinotropic Polypeptide receptor), which is highly expressed in a subset of neuroendocrine tumors (NETs). Since not all NETs can be treated with the currently available somatostatin receptor (sstr)-targeted radiopharmaceuticals such as Lutathera®, we aim to provide an alternative radiopharmaceutical treatment for sstr-negative and Lutathera®-ineligible patients. The GIP receptor program is developed by 3BP and will enter clinical development in late 2021.
3B-301 / Debio 0228 targets carbonic anhydrase IX (CAIX) which is constitutively expressed in clear cell renal cell carcinoma and mesothelioma. In addition, CAIX is expressed in tumors of several different indications in areas that lack oxygen in an effort of the tumor to survive under low oxygen conditions. The program is partnered with Debiopharm International SA who has acquired exclusive worldwide rights to the program and plans to advance the program to clinical trials within two years.